Therapeutic Kinase Inhibitors

Nonfiction, Health & Well Being, Medical, Specialties, Oncology
Cover of the book Therapeutic Kinase Inhibitors by , Springer Berlin Heidelberg
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783642282966
Publisher: Springer Berlin Heidelberg Publication: November 27, 2012
Imprint: Springer Language: English
Author:
ISBN: 9783642282966
Publisher: Springer Berlin Heidelberg
Publication: November 27, 2012
Imprint: Springer
Language: English

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. 

This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. 

This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.

More books from Springer Berlin Heidelberg

Cover of the book Mathematik und Gott und die Welt by
Cover of the book Arbeits-, Organisations- und Personalpsychologie für Bachelor by
Cover of the book Sicherheit von Leichtwasserreaktoren by
Cover of the book Operative Manual of Endoscopic Surgery by
Cover of the book A Prehistory of Polymer Science by
Cover of the book Occupational Cancer Epidemiology by
Cover of the book Colposcopy in Diagnosis and Treatment of Preneoplastic Lesions by
Cover of the book Structure Theory for Canonical Classes of Finite Groups by
Cover of the book Berufsethos kontra Ökonomie by
Cover of the book Signal Conditioning by
Cover of the book Entrepreneurship by
Cover of the book The Research Report on Application of Low-carbon Technology in Expo 2010 Shanghai by
Cover of the book Intellectual Property Rights in China by
Cover of the book Basiswissen Physik, Chemie und Biochemie by
Cover of the book The Human Female Reproductive Tract by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy